Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah B Laskey

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
JCI Insight|November 25, 2016
Quantitative evaluation of the antiretroviral efficacy of dolutegravirSarah B Laskey, Robert F Siliciano
Nature Reviews. Microbiology|September 30, 2014
A mechanistic theory to explain the efficacy of antiretroviral therapySarah B Laskey, Robert F Siliciano
Plos Pathogens|August 6, 2016
Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict ClonalitySarah B Laskey, Christopher W Pohlmeyer, Katherine M Bruner, et al.
Nature|November 24, 2017
Re-evaluating evolution in the HIV reservoirDaniel I S Rosenbloom, Alison L Hill, Sarah B Laskey, et al.
Scientific Reports|May 8, 2020
Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestryRuth I Tennen, Sarah B Laskey, Bertram L Koelsch, et al.
Cell|November 19, 2013
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cureYa-Chi Ho, Liang Shan, Nina N Hosmane, et al.
ACS Medicinal Chemistry Letters|October 22, 2015
Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine ResistanceWilliam T Gray, Kathleen M Frey, Sarah B Laskey, et al.
Nature Medicine|August 9, 2016
Defective proviruses rapidly accumulate during acute HIV-1 infectionKatherine M Bruner, Alexandra J Murray, Ross A Pollack, et al.
Plos One|February 22, 2018
Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responsesChristopher W Pohlmeyer, Sarah B Laskey, Sarah E Beck, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
JCI Insight|November 25, 2016
Quantitative evaluation of the antiretroviral efficacy of dolutegravirSarah B Laskey, Robert F Siliciano
Nature Reviews. Microbiology|September 30, 2014
A mechanistic theory to explain the efficacy of antiretroviral therapySarah B Laskey, Robert F Siliciano
Plos Pathogens|August 6, 2016
Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict ClonalitySarah B Laskey, Christopher W Pohlmeyer, Katherine M Bruner, et al.
Nature|November 24, 2017
Re-evaluating evolution in the HIV reservoirDaniel I S Rosenbloom, Alison L Hill, Sarah B Laskey, et al.
Scientific Reports|May 8, 2020
Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestryRuth I Tennen, Sarah B Laskey, Bertram L Koelsch, et al.
Cell|November 19, 2013
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cureYa-Chi Ho, Liang Shan, Nina N Hosmane, et al.
ACS Medicinal Chemistry Letters|October 22, 2015
Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine ResistanceWilliam T Gray, Kathleen M Frey, Sarah B Laskey, et al.
Nature Medicine|August 9, 2016
Defective proviruses rapidly accumulate during acute HIV-1 infectionKatherine M Bruner, Alexandra J Murray, Ross A Pollack, et al.
Plos One|February 22, 2018
Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responsesChristopher W Pohlmeyer, Sarah B Laskey, Sarah E Beck, et al.
Pageof 1